U.S. Markets closed

Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)

Shanghai - Shanghai Delayed Price. Currency in CNY
Add to watchlist
38.94+1.85 (+4.99%)
At close: 03:00PM CST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close37.09
Bid38.94 x 0
Ask38.95 x 0
Day's Range36.86 - 39.00
52 Week Range27.00 - 66.66
Avg. Volume54,230,682
Market Cap249.061B
Beta (5Y Monthly)0.46
PE Ratio (TTM)39.65
EPS (TTM)0.98
Earnings DateApr 18, 2022 - Apr 22, 2022
Forward Dividend & Yield0.17 (0.56%)
Ex-Dividend DateJun 10, 2021
1y Target Est52.59
  • Bloomberg

    The Unsung Winners and Biggest Losers of China's Rocky Markets in 2021

    (Bloomberg) -- In a year that’s seen China’s “common prosperity” agenda roil global equity markets, the nation’s policies also created a greater divide between stock winners and losers at home.Most Read from BloombergWHO Downplays Threat of Covid-19 Variant Found in FranceU.S. Logs Record 1 Million Virus Cases With Data DelayOmicron Cases Are Hitting Highs, But New Data Put End in SightHong Kong Scraps Flights, Shuts Bars, Gyms on Omicron ThreatHong Kong Vaccine Surge Sees Majority Pick Sinovac

  • Benzinga

    BeyondSpring Inks Plinabulin Agreement In Greater China

    BeyondSpring Inc (NASDAQ: BYSI) and Jiangsu Hengrui Pharmaceuticals Co Ltd have entered into an exclusive commercialization and co-development agreement for plinabulin in Greater China. In combination with G-CSF, Plinabulin is currently under FDA Priority Review and the China National Medical Products Administration for the prevention of chemotherapy-induced neutropenia (CIN). Related Content: BeyondSpring Stock Is Up More than 300%: What You Need To Know? BeyondSpring's 58%-owned subsidiary, Wa